Proteins and Peptides

11 Sep 2017 IRX Therapeutics Presents Positive IRX-2 Phase 2a Head and Neck Squamous Cell Carcinoma Clinical Results at the European Society for Medical Oncology Annual Congress 2017
11 Sep 2017 Radius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
08 Sep 2017 ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
07 Sep 2017 BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017
07 Sep 2017 Bayer submits marketing authorization application for BAY94-9027 for the treatment of Hemophilia A in the EU
06 Sep 2017 Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
06 Sep 2017 Catalyst Biosciences Announces Positive Factor IX Clinical Data
06 Sep 2017 Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Completion of First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
05 Sep 2017 Medtronic Launches Long Term Clinical Study Program of INFUSE Bone Graft in Two Common Spine Procedures: PLF and TLIF
05 Sep 2017 Cinfa Biotech reports clinical development data for pegfilgrastim biosimilar candidate B12019 at the ESMO Congress 2017
02 Sep 2017 Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL
31 Aug 2017 Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis
31 Aug 2017 FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label
31 Aug 2017 Bayer submits Biologics License Application in the U.S. for BAY94-9027 – a long-acting factor VIII for the treatment of Hemophilia A
30 Aug 2017 FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation
29 Aug 2017 Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
26 Aug 2017 Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events
24 Aug 2017 Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest™ (oral leuprolide tablet) for Endometriosis
24 Aug 2017 Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
23 Aug 2017 Bonti Announces Start of LANTERN-1 Phase 2 Clinical Study Evaluating EB-001 in Reducing Musculoskeletal Pain
23 Aug 2017 Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma
23 Aug 2017 Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients
22 Aug 2017 Phase 1 trials for two novel treatments of obesity and/or diabetes initiated by Zealand partner Boehringer Ingelheim
21 Aug 2017 BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
17 Aug 2017 Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up